Contribute Try STAT+ Today

Amid national angst over the cost of prescription drugs, a new analysis finds that U.S. consumers and insurers last year paid anywhere from two to four times as much for 20 brand-name medicines than what were paid in Australia, Canada, and France.

For instance, the cost for a one-month supply of the Xarelto, which is used to combat blood clots, was $272 in the U.S. for those with some form of health insurance, but between $64 and $78 in the other countries. A three-month supply of the Imbruvica cancer pill cost an estimated $13,809 in the U.S., while cancer patients in the other three countries paid between $6,011 and $7,120.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.